DARPP-32 [p Thr75] Antibody NB300-234 from Novus Biologicals, a Bio-Techne Brand

Product Specs
ItemDARPP-32 [p Thr75] Antibody
CompanyNovus Biologicals, a Bio-Techne Brand
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberNB300-234
ImmunogenSynthetic phospho-peptide corresponding to amino acid residues surrounding Thr75 conjugated to KLH. Accession # Q6J4I0
NCBI Gene AliasesDARPP32, Darpp32, DARPP-32, Darpp-32
Format10mM HEPES (pH 7.5), 0.15M NaCl, 0.1 mg/ml BSA and 50% Glycerol
HostRabbit
Quantity0.1 ml
ApplicationsWestern Blot
ReactivityMouse, Rat
TargetDARPP-32
Conjugate/TagUnconjugated
NCBI Full Gene Nameprotein phosphatase 1, regulatory (inhibitor) subunit 1B, protein phosphatase 1 regulatory inhibitor subunit 1B
Modificationsp Thr75
Brand/TrademarkNovus Biologicals, a Bio-Techne Brand
ClonalityPolyclonal
PurityAntigen Affinity-purified
Molecular Weight32 kDa
Research AreaBreast Cancer, Neuronal Cell Markers, Neuroscience, Neurotransmission, Phospho Specific, Protein Phosphatase, Signal Transduction
IsotypeIgG
Antibody TypePrimary Antibodies
StorageStore at -20C. Avoid freeze-thaw cycles

Available conjugates: Unconjugated

Specificity: Specific for endogenous levels of the ~32 kDa DARPP-32 protein phosphorylated at Thr75

United States: 10771 E Easter Ave

Centennial, Colorado 80112

United States

Phone:
303-730-1950
888-506-6887

Email: novus@novusbio.com

(1) Agmatine attenuates reserpine-induced oral dyskinesia in mice: Role of oxidative stress, nitric oxide and glutamate NMDA receptorsBehavioural brain researchOctober 1, 2016Cunha AS, Matheus FC, Moretti M, Sampaio TB, Poli A, Santos DB, Colle D, Cunha MP, Blum-Silva CH, Sandjo LP, et al.

(2) Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancersBreast cancer research and treatmentFebruary 1, 2010Hamel S, Bouchard A, Ferrario C, Hassan S, Aguilar-Mahecha A, Buchanan M, Quenneville L, Miller W, Basik M.

(3) Diverse psychotomimetics act through a common signaling pathwayScience (New York, N.Y.)November 21, 2003Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M, McKinzie DL, Fienberg AA, Nomikos GG, Greengard P.

(4) Involvement of DARPP-32 phosphorylation in the stimulant action of caffeineNatureAugust 15, 2002Lindskog M, Svenningsson P, Pozzi L, Kim Y, Fienberg AA, Bibb JA, Fredholm BB, Nairn AC, Greengard P, Fisone G.

(5) DARPP-32 and regulation of the ethanol sensitivity of NMDA receptors in the nucleus accumbensNature neuroscienceJuly 1, 2002Maldve RE, Zhang TA, Ferrani-Kile K, Schreiber SS, Lippmann MJ, Snyder GL, Fienberg AA, Leslie SW, Gonzales RA, Morrisett RA.

(6) The neurobiology of slow synaptic transmissionScience (New York, N.Y.)November 2, 2001Greengard P.

(7) Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neuronsNatureDecember 9, 1999Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, Czernik AJ, et al.

(8) DARPP-32: regulator of the efficacy of dopaminergic neurotransmissionScience (New York, N.Y.)August 7, 1998Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, Nishi A, Cheramy A, O'Callaghan JP, Miller DB, Cole DG, et al.

(9) DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localizationThe Journal of neuroscience : the official journal of the Society for NeuroscienceJanuary 1, 1984Ouimet CC, Miller PE, Hemmings HC Jr, Walaas SI, Greengard P.

DARPP-32 [p Thr75] Antibody